BioSpace News Archive

Excision BioTherapeutics, Inc. today announced the initiation of a first-in-human (FIH) Phase 1/2 clinical trial of EBT-101 in individuals living with human immunodeficiency virus type 1 (HIV).

Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer’s disease, including details of the study’s goal for diverse enrollment and primary endpoint.

Revelation Pharma, a portfolio company of Osceola Capital, announced today that it has completed the acquisitions of five compounding pharmacies, to include: Innovation Compounding, Pencol Compounding Pharmacy, Pharmacy Specialists Compounding, Wise Compounding, and Convex Pharmacy.

Mitotech today announced that it will host a key opinion leader (KOL) webinar on Visomitin and its potential for the treatment of dry eye disease, on Friday, February 4, 2022 at 8:00 AM EST (14.00 CET).

Yamo Pharmaceuticals today announced that the first patient has been treated in a Phase 2 study of L1-79 in adolescents and young adults with ASD at six U.S. research centers of excellence.

PDS Biotechnology Corporation today announced preclinical data for its universal flu vaccine, which was shown to be effective against multiple strains of the influenza virus.

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st December 2021 (Q2 FY22).

Cocrystal Pharma, Inc. has selected two investigational novel antiviral drug candidates for further development as oral treatments for SARS-CoV-2, the virus that causes COVID-19.

Insmed Incorporated today announced that it will release its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022.

Lipocine Inc. today announced the peer-reviewed publication of positive Phase 3 clinical data from the Dosing Validation (“DV”) study which evaluated the fixed-dose oral testosterone undecanoate, TLANDO, for the treatment of hypogonadism.